Show simple item record

dc.contributor.authorCheadle, Eleanor J
dc.contributor.authorSidon, Lauren
dc.contributor.authorDovedi, Simon J
dc.contributor.authorMelis, M
dc.contributor.authorAlduaij, Waleed
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorHoneychurch, Jamie
dc.date.accessioned2013-08-06T14:50:01Z
dc.date.available2013-08-06T14:50:01Z
dc.date.issued2013-06-18
dc.identifier.citationThe induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. 2013: Br J Haematolen_GB
dc.identifier.issn1365-2141
dc.identifier.pmid23772929
dc.identifier.doi10.1111/bjh.12427
dc.identifier.urihttp://hdl.handle.net/10541/297464
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to British journal of haematologyen_GB
dc.titleThe induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.en
dc.typeArticleen
dc.contributor.departmentTargeted Therapy Group, Paterson Institute for Cancer Research, Institute of Cancer Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.en_GB
dc.identifier.journalBritish Journal of Haematologyen_GB


This item appears in the following Collection(s)

Show simple item record